Scholar Rock Has Dosed The First Participants In The Phase 2 EMBRAZE Proof-of-concept Trial Of Apitegromab To Preserve Lean Muscle Mass In Individuals Living With Obesity And On Background Therapy Of A GLP-1 Receptor Agonist

6/24/24 7:13:08 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SRRK alert in real time by email

The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy. The results from this trial will inform the development of SRK-439, a novel investigational selective myostatin inhibitor optimized for the treatment of cardiometabolic disorders, including obesity.

Get the next $SRRK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SRRK

Date	Price Target	Rating	Analyst
10/7/2024	$30.00 → $35.00	Buy	H.C. Wainwright
3/28/2024	$30.00	Strong Buy	Raymond James
10/25/2023	$20.00	Hold → Buy	Jefferies
4/3/2023	$26.00	Overweight	Piper Sandler
9/19/2022	$30.00	Buy	H.C. Wainwright
7/12/2022	$20.00	Buy	Truist
3/23/2022	$24.00	Buy	H.C. Wainwright
12/22/2021	$52.00 → $28.00	Buy → Hold	Jefferies

More analyst ratings

$SRRK
Press Releases

Fastest customizable press release news feed in the world

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Scholar Rock website at http://investors.scholarrock.com. To pa
11/1/24 8:00:00 AM ET
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scholar Rock to Participate in Upcoming Investor Conferences
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Truist Securities BioPharma Symposium: Scholar Rock is scheduled to participate in a panel presentation at 3:25 p.m. ET on Thursday, November 7 in New York City. Jefferies London Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 4:30 p.m. GMT on Wednesday, November 20 in London. Piper Sandler 36th Annual H
10/31/24 4:00:00 PM ET
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
Poster presentation to include new safety, efficacy, and biomarker data from the long-term expansion phase of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present data from the Phase 1 DRAGON trial of SRK-181, an investigational selective inhibitor of latent TGFβ1 activation, in patients with advanced solid tumors at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meet
10/31/24 8:00:00 AM ET
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024, at 8:15am ET. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Scholar Rock website at http://investors.scholarrock.com. To pa
11/1/24 8:00:00 AM ET
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scholar Rock to Participate in Upcoming Investor Conferences
Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Truist Securities BioPharma Symposium: Scholar Rock is scheduled to participate in a panel presentation at 3:25 p.m. ET on Thursday, November 7 in New York City. Jefferies London Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 4:30 p.m. GMT on Wednesday, November 20 in London. Piper Sandler 36th Annual H
10/31/24 4:00:00 PM ET
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
Poster presentation to include new safety, efficacy, and biomarker data from the long-term expansion phase of the DRAGON trial in patients with advanced solid tumors treated with SRK-181 Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present data from the Phase 1 DRAGON trial of SRK-181, an investigational selective inhibitor of latent TGFβ1 activation, in patients with advanced solid tumors at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meet
10/31/24 8:00:00 AM ET
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Scholar Rock Has Dosed The First Participants In The Phase 2 EMBRAZE Proof-of-concept Trial Of Apitegromab To Preserve Lean Muscle Mass In Individuals Living With Obesity And On Background Therapy Of A GLP-1 Receptor Agonist

Chat with this insight

Recent Analyst Ratings for $SRRK

$SRRK Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

Samsara Biocapital Gp, Llc bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

Invus Public Equities, L.P. bought $15,086,736 worth of shares (2,199,931 units at $6.86) (SEC Form 4)

$SRRK Press Releases

Fastest customizable press release news feed in the world

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

$SRRK Large Ownership Changes

This live feed shows all institutional transactions in real time.

$SRRK Financials

Live finance-specific insights

$SRRK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$SRRK Leadership Updates

Live Leadership Updates

Amendment: SEC Form SC 13D/A filed by Scholar Rock Holding Corporation

Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

SEC Form SC 13G filed by Scholar Rock Holding Corporation

Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

Raymond James initiated coverage on Scholar Rock with a new price target

Scholar Rock upgraded by Jefferies with a new price target

Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

$SRRK SEC Filings

Scholar Rock Holding Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

SEC Form 424B5 filed by Scholar Rock Holding Corporation

SEC Form FWP filed by Scholar Rock Holding Corporation

$SRRK Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $30 Price Target

Scholar Rock Has Dosed The First Participants In The Phase 2 EMBRAZE Proof-of-concept Trial Of Apitegromab To Preserve Lean Muscle Mass In Individuals Living With Obesity And On Background Therapy Of A GLP-1 Receptor Agonist

BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $31

$SRRK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

COO & CFO Myles Edward H exercised 37,187 shares at a strike of $10.00 and sold $1,297,659 worth of shares (37,187 units at $34.90) (SEC Form 4)

COO & CFO Myles Edward H sold $5,477,546 worth of shares (206,240 units at $26.56), decreasing direct ownership by 72% to 161,088 units (SEC Form 4)

CHIEF COMMERCIAL OFFICER Sacco Tracey exercised 30,000 shares at a strike of $10.00 and sold $768,677 worth of shares (30,000 units at $25.62) (SEC Form 4)

Recent Analyst Ratings for
$SRRK

$SRRK
Insider Purchases

$SRRK
Press Releases

$SRRK
Large Ownership Changes

$SRRK
Financials

$SRRK
Analyst Ratings

$SRRK
Leadership Updates

$SRRK
SEC Filings

$SRRK
Market Insights

$SRRK
Insider Trading